Ambry Genetics Announces Launch of Illumina HiSeq 2000 Next Gen Sequencing Services

December 09, 2010

FOR IMMEDIATE RELEASE

Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656


Aliso Viejo, CA – December 9, 2010 – Ambry Genetics, a global leader in genomic services to the healthcare and life sciences industries, announced today that it has officially launched their Illumina HiSeq 2000 Next Generation Sequencing Services. Ambry Genetics has been an early adapter of Illumina sequencing systems since 2007 and has extensive experience as a Certified Service Provider.

"We've continued to invest and develop our sequencing operations to become Illumina experts" said Ardy Arianpour, Vice President of Business Development at Ambry Genetics. "All of our customers are excited about the Illumina HiSeq because it expands our whole genome and exome sequencing services to the next level and gives them the opportunity to reduce their costs while providing more data. If Illumina is your preferred platform then we want to be your preferred sequencing provider."

Ambry Genetics has been at the forefront of applying new sequencing technologies that best meet our clients' needs. A team of scientists routinely process libraries for all available applications ranging from small RNAs to whole genome DNA sequencing. Having sequenced thousands of samples involving a wide range of species including human, mouse, bacteria, viruses, and plants, Ambry is known for its reputation for delivering quality data and service as well as the flexibility in customizing projects to meet the specific needs of researchers. Ambry Genetics will "get your projects done right."


About Ambry Genetics ®

Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.

Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com

Search Results

Start your search...